Stocks
Cortexyme () R&D/CAPEX US GAAP (year values) |
|||||||||
| 2017 | 2018 | 2019 | 2020 | 2021 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 11 817% | 4 757% | 54 935% | 117 898% | 33 775% | 193 447% | |||
| Changes by years, y/y, % | -7 060pp | +50 177pp | +62 964pp | -84 123pp | +30.0% | ||||
Cortexyme. R&D/CAPEX, %
Cortexyme. R&D/CAPEX, changes, pp
Cortexyme () R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2021Q1 | 2021Q2 | 2021Q3 | 2021Q4 | 2022Q1 | LTM ? | |||
| R&D/CAPEX, % | 45 470% | 14 868% | 138 170% | 255 140% | 193 447% | |||
| Changes by years, y/y, % | -242 130pp | -67 991pp | -84 915pp | -20 400pp | +209 670pp | |||
| Changes by quarters, q/q, % | -113 100pp | -30 603pp | -14 868pp | +116 970pp | ||||
